These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

226 related items for PubMed ID: 18049024

  • 1. Renoprotective effect of the addition of losartan to ongoing treatment with an angiotensin converting enzyme inhibitor in type-2 diabetic patients with nephropathy.
    Abe H, Minatoguchi S, Ohashi H, Murata I, Minagawa T, Okuma T, Yokoyama H, Takatsu H, Takaya T, Nagano T, Osumi Y, Kakami M, Tsukamoto T, Tanaka T, Hiei K, Fujiwara H.
    Hypertens Res; 2007 Oct; 30(10):929-35. PubMed ID: 18049024
    [Abstract] [Full Text] [Related]

  • 2. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy.
    Mehdi UF, Adams-Huet B, Raskin P, Vega GL, Toto RD.
    J Am Soc Nephrol; 2009 Dec; 20(12):2641-50. PubMed ID: 19926893
    [Abstract] [Full Text] [Related]

  • 3. Emerging trends for prevention and treatment of diabetic nephropathy: blockade of the RAAS and BP control.
    Hunsicker LG.
    J Manag Care Pharm; 2004 Sep; 10(5 Suppl A):S12-7. PubMed ID: 15369420
    [Abstract] [Full Text] [Related]

  • 4. Dual blockade of the renin-angiotensin-aldosterone system is safe and effective in reducing albuminuria in Asian type 2 diabetic patients with nephropathy.
    Tan F, Mukherjee JJ, Lee KO, Lim P, Liew CF.
    Singapore Med J; 2010 Feb; 51(2):151-6. PubMed ID: 20358155
    [Abstract] [Full Text] [Related]

  • 5. A retrospective study of the effects of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in diabetic nephropathy.
    Pathak JV, Dass EE.
    Indian J Pharmacol; 2015 Feb; 47(2):148-52. PubMed ID: 25878372
    [Abstract] [Full Text] [Related]

  • 6. [Effect of antihypertensive combinations on arterial pressure, albuminuria, and glycemic control in patients with type II diabetic nephropathy: a randomized study].
    Goicolea I, Fernández González R, Piniés J, Garrido J, Martínez JM, Armenteros S, Moreno Carretero E.
    Nefrologia; 2002 Feb; 22(2):170-8. PubMed ID: 12085418
    [Abstract] [Full Text] [Related]

  • 7. Angiotensin receptor antagonist vs. angiotensin-converting enzyme inhibitor in Asian subjects with type 2 diabetes and albuminuria - a randomized crossover study.
    Lim SC, Koh AF, Goh SK, Chua CL, Heng BL, Subramaniam T, Sum CF.
    Diabetes Obes Metab; 2007 Jul; 9(4):477-82. PubMed ID: 17587389
    [Abstract] [Full Text] [Related]

  • 8. Potassium handling with dual renin-angiotensin system inhibition in diabetic nephropathy.
    Van Buren PN, Adams-Huet B, Nguyen M, Molina C, Toto RD.
    Clin J Am Soc Nephrol; 2014 Feb; 9(2):295-301. PubMed ID: 24408116
    [Abstract] [Full Text] [Related]

  • 9. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.
    de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM.
    Kidney Int; 2004 Jun; 65(6):2309-20. PubMed ID: 15149345
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Use of losartan in reducing microalbuminuria in normotensive patients with type-2 diabetes mellitus.
    Agha A, Bashir K, Anwar E.
    Nepal Med Coll J; 2007 Jun; 9(2):79-83. PubMed ID: 17899953
    [Abstract] [Full Text] [Related]

  • 12. Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D).
    Fried LF, Duckworth W, Zhang JH, O'Connor T, Brophy M, Emanuele N, Huang GD, McCullough PA, Palevsky PM, Seliger S, Warren SR, Peduzzi P, VA NEPHRON-D Investigators.
    Clin J Am Soc Nephrol; 2009 Feb; 4(2):361-8. PubMed ID: 19118120
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Antiproteinuric effects of combined antihypertensive therapies in patients with overt type 2 diabetic nephropathy.
    Kuriyama S, Tomonari H, Tokudome G, Horiguchi M, Hayashi H, Kobayashi H, Ishikawa M, Hosoya T.
    Hypertens Res; 2002 Nov; 25(6):849-55. PubMed ID: 12484508
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy.
    Krairittichai U, Chaisuvannarat V.
    J Med Assoc Thai; 2009 May; 92(5):611-7. PubMed ID: 19459520
    [Abstract] [Full Text] [Related]

  • 18. Pharmacologic management of diabetic nephropathy.
    Vivian EM, Rubinstein GB.
    Clin Ther; 2002 Nov; 24(11):1741-56; discussion 1719. PubMed ID: 12501871
    [Abstract] [Full Text] [Related]

  • 19. Angiotensin II type 1 receptor gene polymorphism could influence renoprotective response to losartan treatment in type 1 diabetic patients with high urinary albumin excretion rate.
    Dragović T, Ajdinović B, Hrvacević R, Ilić V, Magić Z, Andelković Z, Kocev N.
    Vojnosanit Pregl; 2010 Apr; 67(4):273-8. PubMed ID: 20465154
    [Abstract] [Full Text] [Related]

  • 20. Long-term effects of addition of mineralocorticoid receptor antagonist to angiotensin II receptor blocker in patients with diabetic nephropathy: a randomized clinical trial.
    Esteghamati A, Noshad S, Jarrah S, Mousavizadeh M, Khoee SH, Nakhjavani M.
    Nephrol Dial Transplant; 2013 Nov; 28(11):2823-33. PubMed ID: 24009294
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.